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Abstract
Background Preparing and submitting a voluntary
adverse event (AE) report to the US Food and Drug
Administration (FDA) for a medical device typically takes
40 min. User-friendly Web and mobile reporting apps
may increase efficiency. Further, coupled with strategies
for direct patient involvement, patient engagement in AE
reporting may be improved. In 2012, the FDA Center for
Devices and Radiologic Health (CDRH) launched a free,
public mobile AE reporting app, MedWatcher, for
patients and clinicians. During the same year, a patient
community on Facebook adopted the app to submit
reports involving a hysteroscopic sterilization device,
brand name Essure.
Methods Patient community outreach was conducted to
administrators of the group ‘‘Essure Problems’’ (approxi-
mately 18,000 members as of June 2015) to gather indi-
vidual case safety reports (ICSRs). After agreeing on key
reporting principles, group administrators encouraged
members to report via the app. Semi-structured forms in
the app mirrored fields of the MedWatch 3500 form. ICSRs
were transmitted to CDRH via an electronic gateway, and
anonymized versions were posted in the app. Data col-
lected from May 11, 2013 to December 7, 2014 were
analyzed. Narrative texts were coded by trained and cer-
tified MedDRA coders (version 17). Descriptive statistics
and metrics, including VigiGrade completeness scores,
were analyzed. Various incentives and motivations to
report in the Facebook group were observed.
Results The average Essure AE report took 11.4 min
(±10) to complete. Submissions from 1349 women,
average age 34 years, were analyzed. Serious events,
including hospitalization, disability, and permanent dam-
age after implantation, were reported by 1047 women
(77.6 %). A total of 13,135 product–event pairs were
reported, comprising 327 unique preferred terms, most
frequently fatigue (n = 491), back pain (468), and pelvic
pain (459). Important medical events (IMEs), most fre-
quently mental impairment (142), device dislocation
(108), and salpingectomy (62), were reported by 598
women (44.3 %). Other events of interest included loss of
libido (n = 115); allergy to metals (109), primarily nickel;
and alopecia (252). VigiGrade completeness scores were
high, averaging 0.80 (±0.15). Reports received via the
mobile app were considered ‘‘well documented’’ 55.9 %
of the time, compared with an international average of
13 % for all medical products. On average, there were 15
times more reports submitted per month via the app with
patient community support versus traditional pharma-
covigilance portals.
Conclusions Outreach via an online patient community,
coupled with an easy-to-use app, allowed for rapid and
detailed ICSRs to be submitted, with gains in efficiency.
Two-way communication and public posting of narratives
led to successful engagement within a Motivation-Incen-
tive-Activation-Behavior framework, a conceptual model
for successful crowdsourcing. Reports submitted by
patients were considerably more complete than those sub-
mitted by physicians in routine spontaneous reports. Fur-
ther research is needed to understand how biases operate
differently from those of traditional pharmacovigilance.
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Key Points
Spontaneous adverse event reporting to the US FDA
was encouraged using an easy-to-use Web and
mobile app along with engagement of a Facebook
patient group, specifically for Essure, a hysteroscopic
sterilization device.
A total of 1349 valid reports were received through
the app over approximately 19 months, equivalent to
15 times more reports than through traditional
channels, with high completeness scores.
The reports were characterized including symptoms
and outcomes reported, and the motivations and
incentives in this engagement model for
pharmacovigilance are discussed.
1 Introduction
It is widely acknowledged that once medical products are
on the market, adverse events (AEs) are severely underre-
ported [1, 2]. While legally binding reporting from manu-
facturers to regulatory agencies and formal post-marketing
studies are conducted, capturing complete information
continues to be a challenge. The challenge is exacerbated
for implantable medical devices, midst pharmacoepidemi-
ology practice developed largely for drugs or biologics [3].
For example, in the USA, nearly a third of mandatory
reports from device manufacturers are delivered later than
the 5-day requirement, creating bottlenecks in which
information becomes lost, misinterpreted, or delayed [4].
Meanwhile, patient-reported outcomes are now accepted
for clinical trials with new medical products [5], and we
have seen renewed focus on patient-reported outcomes in
comparative effectiveness research [6, 7]. However, only
2 % of post-marketing reports about medical devices
received by the US Food and Drug Administration (FDA)
come from patients [8]. Part of the reason for low patient
participation is likely due to reporting burden; the FDA
estimates it takes from 40 to 73 min to complete a report
for a medical device using the MedWatch 3500 (voluntary)
and MedWatch 3500A (mandatory) forms, respectively [9].
While patient reporting for drugs has been shown to be a
valuable addition, with many countries encouraging this
practice [10–13], the same has not been seen for medical
devices; whether patient reporting for implantable medical
devices can provide high-quality, complete, and novel
information remains an open question.
Despite limited patient engagement in device AE
reporting, online tools have served to expand participation
in public health reporting, generally termed ‘‘digital disease
detection.’’ These tools have been applied in monitoring
infectious diseases [14], and ‘‘crowdsourcing’’ or ‘‘partici-
patory epidemiology’’ efforts in this domain have proven
especially successful [15]. Crowdsourcing consists of sys-
tematic efforts to collect information from a wide audience,
particularly through the use of online tools, that are mutu-
ally beneficial to the participants and activity sponsors [16].
Keating and Furberg’s conceptual framework for crowd-
sourcing, known as the Motivation-Incentive-Activation-
Behavior (MIAB) model, deconstructs crowdsourcing into
components that are required for its successful implemen-
tation [17]. While successful crowdsourcing requires open
and active communication between participants and spon-
sors, existing pharmacovigilance practices typically yield
limited feedback and communication.
The objective of this study was to assess the potential for
participatory epidemiology in post-marketing medical
device surveillance, specifically by engaging an online
patient community to encourage submission of individual
case safety reports (ICSRs) through an online tool. We
evaluated the quality of data collected through a Web and
mobile app called MedWatcher and applied the MIAB
framework to characterize successful patient engagement.
The device of interest is Essure (Bayer HealthCare Phar-
maceuticals, Inc., Parsippany, NJ, USA), the first hystero-
scopic sterilization device approved in the USA [18, 19].
This class III device contains an inner coil of stainless steel
with polyethylene fibers and an outer coil of titanium-nickel
[20]. The coil is placed into each fallopian tube during an
outpatient visit, and is promoted as ‘‘permanent birth con-
trol.’’ Subsequent tissue growth around the coil occludes the
fallopian tubes, with a confirmatory test 3 months post-
procedure to confirm correct placement and blockage [21].
2 Methods
2.1 Data Sources
MedWatcher is a Web and mobile app developed by Epi-
demico (Boston, MA, USA) and launched in September
2012, freely available to the US public for streamlined and
user-friendly AE reporting to the FDA. MedWatcher was
developed in partnership with the FDA Center for Devices
and Radiologic Health (CDRH) to overcome the limita-
tions posed by traditional reporting methods. It is available
in English language, on iOS [22] or Android [23] devices
as well as on a mobile-optimized website.
Using MedWatcher, patients and physicians can submit
AEs for medical devices, drugs, vaccines, and biologics.
The app’s report form corresponds to the fields of the
MedWatch 3500 form and requires an event description and
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email address. Optional fields include sex, age, event out-
come, and image file. Users receive an email confirmation
with the content of their report, formatted to allow printing
and sharing with their care providers. In parallel, the system
automatically prepares the ICSR in an E2B format [24].
ICSRs are processed in a secure cloud computing envi-
ronment, manually reviewed to remove spam and test
submissions, and transmitted electronically to CDRH using
a dedicated voluntary reporting gateway, where automatic
consistency, formatting, and completeness checks are con-
ducted before each report is entered into the Manufacturer
and User Facility Device Experience (MAUDE) database.
Two-way communication through the gateway allows
for FDA case report numbers to be provided back to the
patient via the app, enabling consolidation of follow-up
reports. As stated in the terms of service for the app, the
narrative text of each report is de-identified and shared
publicly with other app users, fostering a sense of com-
munity and creating a source for safety information. For
this analysis, we obtained public, redacted narratives
involving Essure from the MedWatcher website [25],
starting from the first submitted report (May 11, 2013)
through to December 7, 2014.
2.2 Product Selection
We selected Essure as the product of analysis because it
was the most frequently reported product via the Med-
Watcher app. Of the 3290 MedWatcher reports received as
of June 2015, 2600 involve Essure. We also had significant
and successful patient engagement with Essure users
through social media.
Essure was originally approved in the USA in 2002. The
‘‘Summary of Safety and Effectiveness’’ reported AEs
during pivotal trials, differentiating between those that
happened on the day of implantation and those that
occurred during 1 year of follow-up [26]. The top five
events on the day were cramping, pain, nausea/vomiting,
dizziness/light headedness, and bleeding/spotting. The top
five events in the first year of follow-up were (lower) back
pain, abdominal pain/cramps, dyspareunia (painful sexual
intercourse), pain/discomfort, and dysmenorrhea (men-
strual cramps). While allergy to metals was not observed in
clinical trials, it was mentioned as a possibility in the
‘‘Warnings’’ section of the label.
A more recent FDA review of the 943 Essure AEs
received from November 4, 2002 to October 25, 2013
found: ‘‘The most frequently reported adverse events were
pain (606), haemorrhage [bleeding] (140), headache (130),
menstrual irregularities (95), fatigue (88), and weight fluc-
tuations (77). The most frequent device problems reported
were the migration of the device or device component
(116), patient device incompatibility (113) (e.g., possible
nickel allergy), device operating differently than expected
(73), malposition of the device (46), and device breakage
(37)’’ [27]. The FDA received one report from a physician
about a death due to necrotizing Streptococcus spp. infec-
tion associated with the device, although the manufacturer
explains that ‘‘the medical opinion of the attending physi-
cian was that the cause of death was not directly related to
the essure [sic] inserts or procedure’’ [28]. Academic
researchers noted tubal perforation [29], pain [30, 31], and
placement failures [32] in clinical routine practice.
2.3 Patient Community Outreach
‘‘Essure Problems’’ is a Facebook group [33] launched in
March 2011 by Angie Firmalino, a patient experiencing sev-
ere AEs following Essure implantation. Since launch, patients
organically joined the Facebook group, and as of June 2015,
there were 17,850 members, managed by 11 volunteer
administrators. The group provides an environment where
patients can share information and experiences regarding
Essure, including an organized directory of files such as
doctors offering device removal, a list of symptoms experi-
enced by members, and a collection of publications and arti-
cles about the product. Discussions of benefits also occur, but
the group was formed largely in the context of harm. In
October 2013, a representative from the MedWatcher app
development team (co-author CYB) joined the group to pro-
vide technical support to patients filingAE reports to the FDA.
Through active engagement in the patient community,
factors that contributed to participation in reporting were
observed by applying the MIAB model. In this model,
‘‘motivation’’ is the reason for interest, and ‘‘incentive’’ is
what leads someone to act. ‘‘Activation’’ is the set of
factors that lead to actual participation, and ‘‘behavior’’ is
the activity of interest and outcome, in this case, submitting
an AE report [17]. Specifically during engagement of the
Facebook patient group, factors that acted as motivation
and incentive that were distinct from traditional reporting
channels were noted.
In preparation for the present study, a series of discus-
sions were initiated with the Facebook group administra-
tors, starting February 2014, to explain the intent for a
research publication. Two administrators of the Facebook
group were elected to participate in the research process
(co-authors MG and KD), and additional discussions clar-
ified the use of a regulatory coding ontology, appropriate
interpretation of spontaneous data, and expectations for the
peer-review process. Concepts of legitimacy and integrity
were clarified on both sides, and there was agreement that
the results would be prepared for publication regardless of
the content of the data received. The outcomes of discus-
sions were communicated back to the Facebook group
administrators or the entire group.
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2.4 Coding Adverse Events (AEs)
AE symptoms reported in mobile app reports were tagged
by two certified MedDRA coders (co-authors CYB and
CEP) using the MedDRA (Medical Dictionary for Regu-
latory Activities) version 17 at the preferred term (PT)
level [34]. All reports were in English. The two coders
jointly tagged the first 20 reports to establish coding
guidelines then proceeded to code the remaining reports
independently, maintaining a living document of codes and
coding guidelines, which were iteratively discussed and
updated.
2.5 VigiGrade Completeness Scores
VigiGrade completeness scores, developed by the Uppsala
Monitoring Centre of the World Health Organization
(WHO-UMC), were calculated based on rules outlined by
Bergvall et al. [35]. VigiGrade completeness scores have
been used routinely in the WHO’s safety report database,
VigiBase, since 2010. Dimensions accounted for in the
VigiGrade completeness score include time-to-onset,
indication, outcome, sex, age, dose, country, primary
reporter’s occupation, report type, and the presence of
informative free-text information. Possible scores range
from 0.07 to 1.0, with each report starting at 1.0 and then
subsequently penalized for each dimension lacking or
containing limited information.
Since Essure is a device with only one indication (per-
manent female birth control) and no off-label use was
noted, there was limited opportunity to penalize for indi-
cation or dose. Because the MedWatcher app is intended
for submission to the US FDA, the assumption was made
that the patients resided in the USA unless otherwise stated
(respondents providing non-US addresses were notified of
a failure to submit to the FDA and then guided to report to
their national authorities). Free-text information was
required on the app’s report form. With these assumptions
and requirements, the lowest score possible for Essure
reports submitted through MedWatcher was 0.139.
2.6 Data Analysis
Consistency and logic checks were used to identify input
and coding errors. Narrative fields were cross-checked for
consistency with structured data elements to correct errors
where possible by directly emailing the reporter for clari-
fication. Events requiring medical care were coded as those
that were life threatening, resulted in a hospital stay or
prolongation of one, or resulted in a visit to the emergency
department. The PT ‘‘nonspecific reaction’’ was not
included in analyses. Important medical events (IMEs)
were identified using the European Medicines Agency list
for MedDRA 17 [36]; the IME list contained 7605 PTs.
Summary and descriptive statistics were calculated in Stata
version 13 (College Station, TX, USA) or visualized in
DataGraph 4 beta (Chapel Hill, NC, USA).
3 Results
A total of 1354 user submissions were received from May
11, 2013 through to December 7, 2014. Four reports were
removed from analysis because of a lack of an identifiable
AE in the narrative, and one report from a male was
removed, for a final sample size of 1349 unique user
reports. Of these, 99 users (7.3 %) submitted a collection of
147 follow-up reports. Many of these ICSRs reported AEs
that occurred before the date of report, and from the launch
of the product in 2002 through 2014, the reported occur-
rence of AEs steadily increased, with most events occur-
ring in 2013 and 2014 (cut off December 7), totaling 614
events over those 2 years (Fig. 1).
3.1 App Usage
The average Essure report took 11.4 min to complete [s-
tandard deviation (SD) 10.0 min, range 0.3–60 min]. Time
spent on submission was available for 64 % of reports, as
this metric was not originally captured by the app; more























Fig. 1 Date of Essure adverse events reported via MedWatcher app.
Most women considered their adverse events to be severe (grey bars).
Asterisk Data for 2014 are complete only through December 7
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A total of 40 submissions resulted in follow-up by Med-
Watcher project staff to solicit additional information or
clarification, in accordance with predetermined rules of
engagement, via email (n = 32; 2.4 %) or private Face-
book Messenger (n = 18; 1.3 %). Facebook Messenger
follow-up was required because of non-responsiveness to
email solicitations; it was later revealed that these users
checked email less frequently than Facebook Messenger or
they had limited access to the email addresses used, which
belonged to spouses or children. Photos were submitted in
12 reports (0.1 %). These photos depicted rashes, x-rays,
endoscopy images, sonograms, product packaging, medical
records, and letters from medical providers (Fig. 2).
3.2 Nature of Reported AEs
Statutorily defined serious events [37] were reported in
1047 cases (77.6 %). The events were serious enough to
require hospitalization and other medical attention in 475
cases (35.2 %), and 382 reports (28.3 %) indicated the
Fig. 2 Selected images for Essure reports submitted via app. Images
for Essure-related adverse events showing a device migration and
b allergic reaction to nickel. Arrow indicates improper location of




















Patient Age in Years
20 25 30 35 40 45 50 55 60
Fig. 3 Ages of reporters by seriousness of event. The average age
reported for Essure events was 34.0 years (standard deviation
































Patient Age in Years
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Fig. 4 Most frequently reported adverse events for Essure. Average
age and 95 % confidence intervals of the 15 most frequently reported
adverse events, by MedDRA preferred term. Sample sizes given
immediately after preferred term. Dotted line represents the average
age of all reporters (33.9 years)
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patient had experienced disability or permanent damage
after implantation of the device.
A total of 13,135 product–event pairs were reported,
comprising 327 unique MedDRA PTs. The average
reported age was 34.0 years (SD 6.1 years), ranging from
21 to 56 years, with serious and non-serious events dis-
tributed consistently over age (Fig. 3).
A total of 327 unique PTs were reported. The number of
unique PTs per submission ranged from 1 to 84, averaging
10.1 (95 % confidence interval 9.6–10.6) per submission.
The most frequently reported PTs included fatigue, back
pain, and pelvic pain (Fig. 4). Of the 1349 reports, 598
(44.3 %) included mention of at least one regulatory-de-
fined IME. The most frequently reported IMEs including
mental impairment and device dislocation are shown in
Fig. 5. Suicidal ideation was reported by 14 women; two
suicide attempts were reported. Other events of interest
include loss of libido (n = 115); allergy to metals (109),
primarily nickel; and alopecia (hair loss) (252).
Some variation in age distribution was observed among
the more common AEs and IMEs (Figs. 4, 5). Average age
was 33.9 years. PTs occurring in women older than aver-
age were device dislocation (35.0 years), arthralgia (joint
pain) (35.2 years), uterine perforation (35.2 years), and
endometrial ablation (scarring of uterus to stop bleeding)
(36.0 years). Younger women more frequently reported
post-procedural haemorrhage (bleeding) (31.9 years) and
spontaneous abortions (miscarriage) (29.5 years).
3.3 Completeness of Reporting
The average length of the free-text narrative field was 104
words, ranging from 3 to 1557; no restrictions on length
were imposed by the app. VigiGrade completeness scores
ranged from 0.2 to 1.0, with an average of 0.80 (SD 0.15).
Time-to-onset information was provided in 858 reports
(63.6 %), with high precision (less than 1-month uncer-
tainty) for 33.0 %. Using the WHO’s threshold for ‘‘well-
documented reports’’ (0.80) [35], 55.9 % (n = 754) of
reports were well documented. Completeness scores did
not vary by age (data not shown). However, average nar-
rative completeness scores were higher among women who
also reported serious AEs using checkboxes (0.83, SD
0.13) compared with those who did not use this feature
(0.61, SD 0.13), suggesting the need to balance structured
and semi-structured fields.
4 Discussion
This analysis presents an approach for encouraging patient
AE reporting via a crowdsourcing tool in collaboration
with online patient community outreach. The inverse
relationship between survey length and response rate is
well studied [38, 39], and it is likely that the efficiency of
reporting, from 40 min via traditional routes to 11.4 min
via the MedWatcher app, contributed to higher volumes of
reports being submitted. During the 132 months after
marketing authorization, CDRH received 943 reports in
MAUDE for Essure (an average of seven per month) [40].
By comparison, there were 1349 reports received via the
app during the 19 months (103 per month) of the study
period (ratio 14.7:1), acknowledging that some reports may
have been submitted via both channels, and that some
events may have occurred years before. For drug AEs in
general, Hoffman et al. have found increasing reports
during the first three quarters after approval and relatively
constant counts after that [41]. While it is unclear how this
pattern may apply for consumer-oriented medical devices,
































Patient Age in Years
25 30 35 40 45
Fig. 5 Most frequently reported important medical events for Essure.
Average age and 95 % confidence intervals of the 15 most frequently
reported important medical events, by MedDRA preferred term.
Sample sizes are presented immediately after preferred term. Dotted
line represents the average age of all reporters (34.0 years)
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occurred a decade after initial marketing is likely related to
the outreach conducted by the Facebook group adminis-
trators and use of the MedWatcher tool.
The MIAB model, Fig. 6, illustrates three key differ-
ences between traditional pharmacovigilance and reporting
via the app with support from a patient community. One
factor that encouraged reporting was the sense of commu-
nity within the Facebook group, in which members vali-
dated each other’s experiences and rallied group members
to submit their reports for common goals. Studies have
shown that altruism, such as the desire to prevent harm to
others and to contribute to research and knowledge, is a
motivator for AE reporting [42]. Two-way communication
creates the opportunity to include an intrinsic motivation—
the validation of patient experience—by leveraging peer
comments as potential reinforcement.
Second, new incentives arise from positive communi-
cations within the patient community, endorsing the app
with reassurance that a group member’s participation will
help other women. This is evidenced by the following posts
in the Facebook group: ‘‘We have an obligation to our
daughters to report it, if we don’t, this could be a viable
birth control option for them’’ and ‘‘If you have had any
problems after being implanted with Essure, please file a
report with the FDA […] That is the only way the FDA
knows what is going on […]. File here. [URL to Med-
Watcher app]’’. The incentive of receiving external vali-
dation and empathy for one’s experience is supported by
public encouragement in the patient community. For
example, when a group member posted a screen capture of
the email confirmation received from the app, others
responded with many Facebook ‘‘likes,’’ a mechanism of
quick, positive response to a post, or comments such as
‘‘Wootwoot! AWESOME!!’’
The third difference with traditional pharmacovigilance
is the presence of feedback loops based on bidirectional



































‘‘Motivation’’ is the reason for
interest, and ‘‘incentive’’ is what
leads someone to act.
‘‘Activation’’ is the set of
factors that lead to actual
participation. ‘‘Behavior’’ is the
activity of interest and outcome,
in this case, submitting an
adverse event report. Dotted
lines represent feedback loops
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communication. One feedback loop resulting from a posi-
tive user experience reinforces the community’s endorse-
ment of the technology. A second feedback loop operates
between the end user and the patient community when
anonymized and redacted reports are publicly posted in the
app. In summary, the collaboration between the mobile app
and Facebook group yielded new incentive structures and
feedback mechanisms by allowing patients to communicate
confidentially with each other and by making anonymized
reports public.
Leverage-salience theory [43] further corroborates that
individual participation in survey research is greater when
community involvement is present. As Keating and Fur-
berg point out, motivation ‘‘is greater if members of an
individual’s social network indicate the importance of
participating in an event’’ [17]. The motivational support
pathways emerged naturally without interference by app
developers or the FDA; deliberate alignment of incentives
is an area for consideration in future efforts. Another
potential enhancement is providing personalized feedback.
Previous research has shown that personalized feedback
from healthcare providers is a key factor in submitting
another AE in the future [44]. While the publicly posted
reports may go some distance in generating feedback
content, further steps can be taken to customize this
information for the reporter.
The reports received via the app were more complete on
average than reports received by regulatory agencies
worldwide. The average VigiGrade completeness score is
0.45 for the 7.0 million reports in VigiBase through to
January 2012 [35], while the reports received via the app
averaged 0.80. Reports received via the app were consid-
ered ‘‘well documented’’ 55.9 % of the time, while the
international average is 13 % [35], in other words, app
reports were more than four times as likely to be well
documented. Further, reports from patients via the app
were more complete than reports completed by physicians
worldwide (for all medical products); only 24 % of reports
from physicians are considered well documented [35].
Since VigiGrade scores vary by country, it is worth noting
that US physicians rank near the bottom of the list globally
in completeness of reports [35]. The information provided
by patients, in 11.4 min on average via the app, was of
much higher quality than anticipated.
While this study highlights the usefulness and value of
online tools in patient reporting, its greatest limitations are
generalizability and replicability. Spontaneous report data
are limited in general by the lack of a patient exposure
denominator. Further, it is unclear what biases may exist in
reports submitted by a particularly active and motivated
group of patients and how their access to technology may
play a role in these biases. Traditional spontaneous report
data originating from patients versus healthcare providers
have typically involved a different breadth of body organ
systems, yet provide similar overall nature of drug prob-
lems [45]. Similar patterns may be present in data reported
via consumer-oriented apps. It will be important in the
future to explore what kinds of biases may operate due to
social stigma that may lead to differential submissions of
certain types of medical events (e.g., those less stigma-
tized) or by certain types of patients (e.g., with more nor-
mative patient identities) at the intersection of social media
and apps. Until these studies are undertaken, there will be
limited direction for how to incorporate stimulated data
into quantitative signal detection methods, especially in
regard to signal-to-noise determination. It also remains to
be seen whether a co-promotion model with patient com-
munities is a sustainable and scalable enterprise. With the
MedWatcher app, similar efforts are already emerging with
other Facebook patient groups.
In addition, the nature of the product (narrow indication,
no notable off-label use) allowed us to make assumptions
that led to higher VigiGrade completeness scores. Due to
the lack of a device-specific completeness metric, Vigi-
Grade was used as the best alternative. While VigiGrade
scores are intended for multi-national comparisons, global
data on medical device reports are not currently available,
making relative completeness of the reports somewhat
difficult to interpret.
Despite these limitations, the FDA has been responsive
to this reporting population. In the June 2014 report, FDA
stated that they ‘‘reviewed Essure patient reports of prob-
lems (including Web-based testimonials) and reports of
problems submitted to the FDA from other sources,
including doctors, patients, and the manufacturer’’ [40].
We applaud the Agency’s efforts to extend the conversa-
tional space for collecting AEs. The Agency went as far as
to meet with representatives of the Facebook group in
February 2014, as a venue to communicate and express the
group’s concerns. Most recently, on June 24, 2015, the
Agency announced that an Advisory Committee Meeting
would be held in September 2015 to discuss risks and
benefits of Essure, citing that ‘‘the majority of reports
received since 2013 have been voluntary reports, mostly
from women who received Essure implants’’ [46].
5 Conclusions
Creating a mobile app that mimics ICSRs provides a
technological solution to the greater medical problem of
underreported AEs. A more holistic solution demonstrated
in the present study is the engagement of patient groups to
responsibly promote use of the app, grounded equally in
social theory and medical informatics. At the heart of the
user experience in this coupled engagement approach is the
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sharing of information, a traditionally sensitive subject in
pharmacovigilance. Impending technological advances
such as automated anonymization can support broader
liberation of ICSR narratives, bringing pharmacovigilance
closer to the ‘‘lively, engaging, dynamic, collaborative,
humane enterprise’’ that it has the potential to be [47].
Acknowledgments The authors thank all the women who shared
their experiences via MedWatcher. The views expressed in this paper
are solely those of the authors and not of the funding source. The
authors acknowledge past and present CDRH collaborators: Fei Wu,
John-William Declaris, Doug Wood, Mary Beth Ritchey, Isaac
Chang, Benjamin Eloff, and Allison Huffman, as well as FDA sci-
entists Bob Ball and Skip Francis. The authors appreciate reviews of
portions of this manuscript by Kristen Bibeau and Roxanne Saucier.
The authors thank the mobile development team for improving the
app: Katelynn O’Brien, Kyra McKenna, and Lucas Baptista. The
authors thank Eric Xu and Carly Winokur for assistance in preparing
this manuscript for submission.
Compliance with Ethical Standards
Funding This research was funded in part by the Center for Devices
and Radiologic Health of the US Food and Drug Administration
(HHSF223201210016C).
Conflict of interest CYB, CCF, CMM, CEP, HR, and ND are
employees, and JSB is a consultant of Epidemico, Inc., a company
attempting to commercialize the information technology aspects of
this research. MG, KD, and RB have no conflict of interest to report.
The manufacturer(s) of Essure are not clients of Epidemico, nor
were they contacted about this research prior to submission. Epi-
demico is a wholly owned subsidiary of Booz Allen Hamilton.
Open Access This article is distributed under the terms of the
Creative Commons Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/by-nc/4.0/), which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided you give appropriate credit to the original
author(s) and the source, provide a link to the Creative Commons
license, and indicate if changes were made.
References
1. Tubert P, Be´gaud B, Pe´re´ JC, et al. Power and weakness of
spontaneous reporting: a probabilistic approach. J Clin Epi-
demiol. 1992;45(3):283–6.
2. Bates DW, Evans RS, Murff H, et al. Detecting adverse events
using information technology. J Am Med Inform Assoc.
2003;10(2):115–28.
3. Jalbert JJ, Ritchey ME, Mi X, et al. Methodological considera-
tions in observational comparative effectiveness research for
implantable medical devices: an epidemiologic perspective. Am J
Epidemiol. 2014;180(9):949–58.
4. United States. Department of Health and Human Services. Office
of Inspector General, Semiannual report. 2009. p. volumes.
5. Guidance for industry: patient-reported outcome measures: use in
medical product development to support labeling claims. 2009
[cited December 2009]; Available from: http://www.fda.gov/
downloads/Drugs/Guidances/UCM193282.pdf.
6. Frank L, Forsythe L, Ellis L, et al. Conceptual and practical
foundations of patient engagement in research at the patient-
centered outcomes research institute. Qual Life Res. 2015;24(5):
1033–41.
7. Costlow MR, Landsittel DP, James III AE, et al. Model for a
patient-centered comparative effectiveness research center. Clin
Transl Sci. 2015;8(2):155–9.
8. Duggirala HJ, Herz ND, Canos DA, et al. Disproportionality
analysis for signal detection of implantable cardioverter-defib-
rillator-related adverse events in the Food and Drug Adminis-
tration Medical Device Reporting System. Pharmacoepidemiol
Drug Saf. 2012;21(1):87–93.
9. Kux L. Agency Information Collection Activities; Proposed
Collection; Comment Request; MedWatch: The Food and Drug
Administration Medical Products Reporting Program. 2014




10. Blenkinsopp A, Wilkie P, Wang M, et al. Patient reporting of
suspected adverse drug reactions: a review of published literature
and international experience. Br J Clin Pharmacol. 2007;
63(2):148–56.
11. Hazell L, Cornelius V, Hannaford P, et al. How do patients
contribute to signal detection? A retrospective analysis of spon-
taneous reporting of adverse drug reactions in the UK’s Yellow
Card Scheme. Drug Saf. 2013;36(3):199–206.
12. Banerjee AK, Okun S, Edwards IR, et al. Patient-Reported Out-
come Measures in Safety Event Reporting: PROSPER Consor-
tium guidance. Drug Saf. 2013;36(12):1129–49.
13. van Hunsel F, Talsma A, van Puijenbroek E, et al. The proportion
of patient reports of suspected ADRs to signal detection in the
Netherlands: case-control study. Pharmacoepidemiol Drug Saf.
2011;20(3):286–91.
14. Hartley DM, Nelson NP, Arthur RR, et al. An overview of
internet biosurveillance. Clin Microbiol Infect. 2013;19(11):
1006–13.
15. Freifeld CC, Chunara R, Mekaru SR, et al. Participatory epi-
demiology: use of mobile phones for community-based health
reporting. PLoS Med. 2010;7(12):e1000376.
16. Estelle´s-Arolas E, Gonza´lez-Ladro´n-de-Guevara F. Towards
an integrated crowdsourcing definition. J Inf Sci. 2012;38(2):
189–200.
17. von Rosenstiel L, Grundlagen-und Bezugsdisziplinen der
Arbeits-und Organisationspsychologie. Handbuch der Arbeits-
und Organisationspsychologie; 2007. p. 17.
18. Kerin JF, Cooper JM, Price T, et al. Hysteroscopic sterilization
using a micro-insert device: results of a multicentre phase II
study*. Hum Reprod. 2003;18(6):1223–30.
19. Cooper JM, Carignan CS, Cher D, et al. Microinsert noninci-
sional hysteroscopic sterilization. Obstet Gynecol. 2003;102(1):
59–67.
20. Valle RF, Carignan CS, Wright TC. Tissue response to the STOP
microcoil transcervical permanent contraceptive device: results
from a prehysterectomy study. Fertil Steril. 2001;76(5):974–80.
21. Your complete guide to the Essure procedure. 2013 [cited 2015
3/26]; Available from: http://www.essure.com/assets/pdf/Patient-
Information-Booklet.pdf.
22. MedWatcher for drugs, vaccines and medical devices. [cited
2015 2/25]; Available from: https://itunes.apple.com/us/app/
medwatcher-for-drugs-vaccines/id391767048?mt=8.
23. MedWatcher drug/device/vaccine. [cited 2015 2/25]; Avail-
able from: https://play.google.com/store/apps/details?id=org.med
watcher&hl=en.
24. MedWatcher Essure. [cited 2014 12/20]; Available from: https://
medwatcher.org/products/Essure.
25. Guidance for Industry. E2B(R3) Electronic transmission of
individual case safety reports (ICSRs) implementation guide. Feb
Facilitating Patient Reporting of Adverse Events Using Online Tools 339
2014 [cited 2015 6/24]; Available from: http://www.fda.
gov/downloads/drugs/guidancecomplianceregulatoryinformation/
guidances/ucm275638.pdf.
26. Summary of safety and effectiveness data. 2002 [cited 2015
3/26]; Available from: http://www.accessdata.fda.gov/cdrh_docs/
pdf2/P020014b.pdf.




28. MAUDE adverse event report: Bayer Healthcare LLC Essure
device, occlusion, tubal, contraceptive. 2013 [cited 2015 2/25];
Available from: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/
cfMAUDE/detail.cfm?mdrfoi__id=3369777.
29. Langenveld J, Sebastiaan V, Bongers MY, et al. Tubal perfora-
tion by Essure: three different clinical presentations. Fertil Steril.
2008;90(5):2011. e5–2011. e10.
30. Syed R, Levy J, Childers ME. Pain associated with hysteroscopic
sterilization. JSLS. 2007;11(1):63–5.
31. Conover MM, Howell JO, Wu JM, et al. Incidence of opioid-
managed pelvic pain after hysteroscopic sterilization versus
laproscopic sterilization, US 2005-2012. Pharmacoepidemiol
Drug Saf. 2015. doi:10.1002/pds.3766.
32. Panel P, Grosdemouge I. Predictive factors of Essure implant
placement failure: prospective, multicenter study of 495 patients.
Fertil Steril. 2010;93(1):29–34.
33. Essure Problems. Facebook group. [cited 2015 3/26]; Available
from: https://www.facebook.com/groups/Essureproblems/.
34. Brown EG, Wood L, Wood S. The Medical Dictionary for
Regulatory Activities (MedDRA). Drug Saf. 1999;20(2):109–17.
35. Bergvall T, Noren GN, Lindquist M. VigiGrade: a tool to identify
well-documented individual case reports and highlight systematic
data quality issues. Drug Saf. 2014;37(1):65–77.
36. EudraVigilance Human. [cited 2014 12/8]; Available from:
https://eudravigilance.ema.europa.eu/human/textforIME.asp.
37. Federal Food, Drug, and Cosmetic Act (FD&C Act). 2006 [cited
2015 6/24]; Available from: http://www.fda.gov/regulatory
information/legislation/federalfooddrugandcosmeticactfdcact/.
38. Sahlqvist S, Song Y, Bull F, et al. Effect of questionnaire length,
personalisation and reminder type on response rate to a complex
postal survey: randomised controlled trial. BMC Med Res
Methodol. 2011;11(1):62.
39. Jepson C, Asch DA, Hershey JC, et al. In a mailed physician
survey, questionnaire length had a threshold effect on response
rate. J Clin Epidemiol. 2005;58(1):103–5.
40. Essure permanent birth control. 2014 [cited 2015 2/25]; Available
from: http://www.fda.gov/medicaldevices/productsandmedical
procedures/implantsandprosthetics/ucm371014.htm#review.
41. Hoffman KB, Dimbil M, Erdman CB, et al. The Weber effect and
the United States Food and Drug Administration’s Adverse Event
Reporting System (FAERS): analysis of sixty-two drugs
Approved from 2006 to 2010. Drug Saf. 2014;37(4):283–94.
42. van Hunsel F, van der Welle C, Passier A, et al. Motives for
reporting adverse drug reactions by patient-reporters in the
Netherlands. Eur J Clin Pharmacol. 2010;66(11):1143–50.
43. Groves RM, Presser S, Dipko S. The role of topic interest in
survey participation decisions. Public Opin Q. 2004;68(1):2–31.
44. Oosterhuis I, van Hunsel FP, van Puijenbroek EP. Expectations
for feedback in adverse drug reporting by healthcare profes-
sionals in the Netherlands. Drug Saf. 2012;35(3):221–32.
45. Inch J, Watson MC, Anakwe-Umeh S. Patient versus healthcare
professional spontaneous adverse drug reaction reporting: a sys-
tematic review. Drug Saf. 2012;35(10):807–18.




47. Hugman B. The fatal love of forms. Drug Saf. 2011;34(8):705.
340 C. Y. Bahk et al.
